WEBULL

Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Simply Wall St · 1d ago

The analysts might have been a bit too bullish on Hansa Biopharma AB (publ) (STO:HNSA), given that the company fell short of expectations when it released its quarterly results last week. It was not a great statutory result, with revenues coming in 76% lower than the analysts predicted. Unsurprisingly, earnings also fell seriously short of forecasts, turning into a per-share loss of kr2.56. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

earnings-and-revenue-growth
OM:HNSA Earnings and Revenue Growth July 25th 2026

After the latest results, the eight analysts covering Hansa Biopharma are now predicting revenues of kr782.7m in 2026. If met, this would reflect a huge 313% improvement in revenue compared to the last 12 months. Statutory losses are forecast to balloon 74% to kr1.92 per share. Before this earnings report, the analysts had been forecasting revenues of kr674.3m and earnings per share (EPS) of kr1.59 in 2026. Yet despite forecasts for higher revenue, the analysts have cut their earnings estimates from a profit to a loss. So it seems there's been a pretty clear dip in sentiment, following the latest results.

View our latest analysis for Hansa Biopharma

There was no major change to the consensus price target of kr73.00, with growing revenues seemingly enough to offset the concern of growing losses. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Hansa Biopharma, with the most bullish analyst valuing it at kr103 and the most bearish at kr36.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. The analysts are definitely expecting Hansa Biopharma's growth to accelerate, with the forecast 16x annualised growth to the end of 2026 ranking favourably alongside historical growth of 25% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 13% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Hansa Biopharma is expected to grow much faster than its industry.

The Bottom Line

The biggest low-light for us was that the forecasts for Hansa Biopharma dropped from profits to a loss next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. The consensus price target held steady at kr73.00, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Hansa Biopharma going out to 2028, and you can see them free on our platform here..

And what about risks? Every company has them, and we've spotted 5 warning signs for Hansa Biopharma (of which 2 are significant!) you should know about.